BridgeBio Pharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held on June 21, 2023. The filing details the voting outcomes for director elections, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for these metrics.
Material Changes and Voting Results
The following proposals were submitted to stockholders, with 148,838,149 shares present or represented by proxy out of 160,500,999 entitled to vote:
- Proposal 1: Election of Directors
- Four Class I directors were elected to serve until the 2026 Annual Meeting.
- James C. Momtazee: 126,983,947 votes for; 6,964,797 withheld.
- Frank McCormick, Ph.D.: 126,128,725 votes for; 7,820,019 withheld.
- Randal W. Scott, Ph.D.: 131,253,639 votes for; 2,695,105 withheld.
- Hannah A. Valantine, M.D.: 107,393,329 votes for; 26,555,415 withheld.
- There were 14,889,405 broker non-votes.
- Proposal 2: Advisory Vote on Executive Compensation
- Stockholders approved the compensation of named executive officers.
- For: 104,001,511 | Against: 29,901,611 | Abstentions: 45,622.
- There were 14,889,405 broker non-votes.
- Proposal 3: Ratification of Independent Auditor
- Stockholders ratified the appointment of Deloitte & Touche LLP for the fiscal year ending December 31, 2023.
- For: 148,795,806 | Against: 21,960 | Abstentions: 20,383.
- There were zero broker non-votes.
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the administrative outcomes of the Annual Meeting.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class I directors (James C. Momtazee, Frank McCormick, Randal W. Scott, and Hannah A. Valantine) through the 2026 Annual Meeting.
- Note the significant number of votes withheld for Director Hannah A. Valantine (26.5 million) compared to other nominees.
- Confirm the approval of executive compensation, noting that approximately 22% of votes cast were against the proposal.
- Review the definitive proxy statement filed on April 28, 2023, for detailed background on the proposals and director biographies.